Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life

by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron
Published 2022-07-01

Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials

by Seemal R. Desai, Linda Stein Gold, Michael C. Cameron, Alexandra Golant, G. Michael Lewitt, Matthew J. Bruno, George Martin, Philip M. Brown, David S. Rubenstein, Victoria Butners, Anna M. Tallman
Published 2023-09-01

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from...

by Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley
Published 2024-12-01

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE

by Melinda J. Gooderham, MSc, MD, FRCPC, Chia-Yu Chu, MD, PhD, Ricardo Rojo, MD, Hernan Valdez, MD, Pinaki Biswas, PhD, Michael C. Cameron, MD, Claire Feeney, MD, PhD, Gerardo A. Encinas, MD, MHS, Kathleen Peeples-Lamirande, PharmD, MPH, Joseph C. Cappelleri, PhD, Daniela E. Myers, MPH, Marco DiBonaventura, PhD
Published 2021-09-01